In Re: James
Opinion for the Court filed by Circuit Judge TATEL.
In this employment discrimination case against a federal agency, the district court denied class certification because, in its view, the employee plaintiffs failed to file their lawsuit within the time required by Title VII of the Civil Rights Act of 1964. Plaintiffs, petitioners herein, now seek to challenge the denial of class certification, invoking
I.
Title VII of the Civil Rights Act of 1964, as amended, prohibits “discrimination based on race, color, religion, sex, or national origin” in federal employment.
Unable to resolve their claims with agency EEO Counselors, petitioners filed individual administrative complaints alleging that their employer, the Naval Sea Systems Command (“NAVSEA”), discriminated against them on the basis of, among other things, sex and/or race. Later, they filed a class complaint together with a motion to certify the matter as a class action. As required by applicable regulations, NAVSEA forwarded the class complaint to the EEOC.
See
Petitioners moved for reconsideration, arguing first that the district court “erred in treating the plaintiffs’ motion for class certification as a challenge” to the EEOC’s March 21 letter dismissing their class complaint, “rather than as a request to certify the plaintiffs as a class pursuant to [
Pursuant to
II.
In re Lorazepam & Clorazepate Antitrust Litigation (“Lorazepam”)
articulates the circumstances under which this circuit will exercise its discretion to entertain
(1) when there is a death-knell situation for either the plaintiff or defendant that is independent of the merits of the underlying claims, coupled with a class certification decision by the district court that is questionable, taking into account the district court’s discretion over class certification; (2) when the certification decision presents an unsettled and fundamental issue of law relating to class actions, important both to the specific litigation and generally, that is likely to evade end-of-the-case review; and (3) when the district court’s class certification decision is manifestly erroneous.
Invoking
Lorazepam’s
third category, petitioners argue that the district court’s denial of class certification was “manifestly erroneous” in two respects. First, they insist that because they administratively exhausted their class claims, and because they timely filed their administrative individual claims, the district court should have certified a
Whatever their merits under Title VII, these arguments suffer from a fatal flaw with respect to
Indeed, this case is indistinguishable from
Lorazepam.
There, several drug companies challenged the certification of a class of direct purchasers, arguing that the district court erred when it failed to determine whether the class and its representatives had standing under the relevant antitrust law to sue for damages.
Id.
at 101— 02. Although the drug companies correctly pointed out that “whether a class of direct purchasers has antitrust standing under the particular circumstances at issue is a novel question of law” that “may dispose of the class as a whole and thereby preclude a lawsuit by direct purchasers,” we found the question “unrelated to the
Attempting to convert their Title VII arguments into
Again, petitioners’ argument suffers from a fatal defect. Before the district court can determine whether petitioners’ complaint qualifies for class status under
Finally, petitioners argue that their claims qualify for
Moreover, even if petitioners’ arguments were jurisdictional, nothing in
Lorazepam
would allow us to consider them in deciding
whether
to grant their
In dismissing this
So ordered.